Levetiracetam (Keppra)
Sponsors
University Hospitals Cleveland Medical Center, Sleep Health Centers, UCB Pharma, Charite University, Berlin, Germany, University of California, San Francisco
Conditions
Alcohol AbuseAlcohol DependenceAlcoholic RelapseBrain Metastases From Extra-cranial Solid TumorsBrain Metastases From Non-small Cell Lung Cancer (NSCLC)Brain Metastases, AdultDrug AbuseEpilepsy
Phase 1
Phase 2
A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)
CompletedNCT00247364
Start: 2003-11-30End: 2005-10-31Target: 20Updated: 2005-11-01
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RecruitingNCT07130786
Start: 2025-12-23End: 2030-02-01Target: 150Updated: 2026-09-08
Phase 3
Phase 4
A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
CompletedNCT00631150
Start: 2003-03-31End: 2004-07-31Updated: 2013-11-15
S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
CompletedNCT00630968
Start: 2000-08-31End: 2004-02-29Updated: 2013-11-15
Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
CompletedNCT00630357
Start: 2003-03-31End: 2004-07-31Updated: 2013-11-15